Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 113 | 2024 | 16764 | 2.880 |
Why?
|
Anti-HIV Agents | 54 | 2021 | 4320 | 2.470 |
Why?
|
Benzoxazines | 23 | 2015 | 306 | 1.650 |
Why?
|
Reverse Transcriptase Inhibitors | 22 | 2022 | 624 | 1.640 |
Why?
|
HIV-1 | 48 | 2023 | 6931 | 1.440 |
Why?
|
Antiretroviral Therapy, Highly Active | 24 | 2019 | 1896 | 1.030 |
Why?
|
Anti-Retroviral Agents | 15 | 2023 | 1734 | 0.990 |
Why?
|
Ritonavir | 9 | 2016 | 324 | 0.930 |
Why?
|
Oxidoreductases, N-Demethylating | 4 | 2013 | 114 | 0.840 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 257 | 0.790 |
Why?
|
HIV Protease Inhibitors | 6 | 2016 | 435 | 0.780 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2023 | 3233 | 0.770 |
Why?
|
Viral Load | 26 | 2022 | 3299 | 0.770 |
Why?
|
Dideoxynucleosides | 9 | 2015 | 124 | 0.760 |
Why?
|
Drug Resistance, Viral | 15 | 2023 | 829 | 0.680 |
Why?
|
Alkynes | 23 | 2015 | 310 | 0.670 |
Why?
|
Cyclopropanes | 23 | 2015 | 421 | 0.640 |
Why?
|
Cardiovascular Diseases | 18 | 2023 | 15070 | 0.640 |
Why?
|
Plaque, Atherosclerotic | 7 | 2023 | 1483 | 0.570 |
Why?
|
Quinolines | 5 | 2023 | 721 | 0.570 |
Why?
|
Randomized Controlled Trials as Topic | 13 | 2022 | 9812 | 0.540 |
Why?
|
Glucuronosyltransferase | 2 | 2012 | 128 | 0.530 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2015 | 2241 | 0.510 |
Why?
|
Unsafe Sex | 1 | 2016 | 220 | 0.510 |
Why?
|
Cyclohexanes | 4 | 2016 | 153 | 0.500 |
Why?
|
RNA, Viral | 18 | 2016 | 2907 | 0.490 |
Why?
|
CD4 Lymphocyte Count | 19 | 2020 | 2602 | 0.480 |
Why?
|
Oxazines | 6 | 2006 | 302 | 0.480 |
Why?
|
Methotrexate | 4 | 2022 | 1711 | 0.460 |
Why?
|
HIV | 11 | 2023 | 1607 | 0.430 |
Why?
|
HIV Seropositivity | 3 | 2020 | 966 | 0.430 |
Why?
|
Coronary Artery Disease | 8 | 2023 | 6416 | 0.430 |
Why?
|
Nevirapine | 5 | 2013 | 273 | 0.390 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2010 | 115 | 0.370 |
Why?
|
Triazoles | 4 | 2016 | 906 | 0.340 |
Why?
|
Treatment Failure | 16 | 2021 | 2614 | 0.340 |
Why?
|
Drug Therapy, Combination | 16 | 2016 | 6478 | 0.320 |
Why?
|
Research Subjects | 2 | 2020 | 237 | 0.320 |
Why?
|
Brachial Artery | 2 | 2020 | 370 | 0.320 |
Why?
|
Oligopeptides | 2 | 2014 | 1179 | 0.320 |
Why?
|
Male | 91 | 2024 | 349022 | 0.270 |
Why?
|
Double-Blind Method | 20 | 2023 | 11985 | 0.260 |
Why?
|
Female | 95 | 2024 | 378853 | 0.260 |
Why?
|
Middle Aged | 65 | 2024 | 212863 | 0.260 |
Why?
|
Humans | 125 | 2024 | 739398 | 0.240 |
Why?
|
Pregnancy Complications, Infectious | 6 | 2016 | 2028 | 0.240 |
Why?
|
Adult | 72 | 2023 | 213394 | 0.240 |
Why?
|
HIV Integrase Inhibitors | 2 | 2023 | 144 | 0.230 |
Why?
|
Medication Adherence | 6 | 2014 | 2047 | 0.210 |
Why?
|
Atherosclerosis | 4 | 2023 | 3401 | 0.210 |
Why?
|
HIV Integrase | 1 | 2023 | 120 | 0.210 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2006 | 812 | 0.210 |
Why?
|
Pyridines | 2 | 2014 | 2810 | 0.200 |
Why?
|
Anti-Inflammatory Agents | 3 | 2022 | 1777 | 0.200 |
Why?
|
HIV Long-Term Survivors | 2 | 2020 | 126 | 0.200 |
Why?
|
Primary Prevention | 4 | 2023 | 1165 | 0.190 |
Why?
|
CD4-CD8 Ratio | 2 | 2020 | 112 | 0.190 |
Why?
|
Multicenter Studies as Topic | 3 | 2020 | 1583 | 0.190 |
Why?
|
Inflammation | 7 | 2023 | 10534 | 0.180 |
Why?
|
Bone Density | 5 | 2017 | 3471 | 0.180 |
Why?
|
Viremia | 2 | 2014 | 733 | 0.170 |
Why?
|
Zidovudine | 7 | 2010 | 623 | 0.160 |
Why?
|
Indinavir | 4 | 2010 | 74 | 0.160 |
Why?
|
Research Design | 2 | 2022 | 5959 | 0.160 |
Why?
|
Lipoproteins, LDL | 2 | 2022 | 626 | 0.160 |
Why?
|
Models, Statistical | 3 | 2022 | 5113 | 0.160 |
Why?
|
Pharmacogenetics | 3 | 2011 | 679 | 0.160 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2016 | 1331 | 0.150 |
Why?
|
Plasma | 3 | 2015 | 573 | 0.150 |
Why?
|
Treatment Outcome | 25 | 2019 | 62693 | 0.150 |
Why?
|
Lamivudine | 6 | 2007 | 342 | 0.150 |
Why?
|
Adenine | 3 | 2014 | 940 | 0.140 |
Why?
|
Osteoporosis | 2 | 2017 | 1576 | 0.140 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4143 | 0.140 |
Why?
|
Ultrasonography, Doppler | 1 | 2018 | 460 | 0.140 |
Why?
|
Vasodilation | 1 | 2020 | 947 | 0.140 |
Why?
|
Endothelium | 1 | 2019 | 776 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 808 | 0.140 |
Why?
|
HIV Seronegativity | 2 | 2020 | 209 | 0.140 |
Why?
|
Body Composition | 3 | 2016 | 2397 | 0.140 |
Why?
|
Nelfinavir | 3 | 2004 | 68 | 0.130 |
Why?
|
Hair | 1 | 2019 | 479 | 0.130 |
Why?
|
Amino Acids | 2 | 2020 | 1727 | 0.130 |
Why?
|
Calcium Carbonate | 1 | 2015 | 67 | 0.130 |
Why?
|
Coronary Disease | 1 | 2010 | 6068 | 0.130 |
Why?
|
Immunomodulation | 1 | 2019 | 540 | 0.130 |
Why?
|
Gender Identity | 1 | 2020 | 674 | 0.120 |
Why?
|
Sexual Partners | 2 | 2016 | 727 | 0.120 |
Why?
|
Condoms | 1 | 2016 | 321 | 0.120 |
Why?
|
Vitamin D | 2 | 2019 | 3197 | 0.120 |
Why?
|
Calcifediol | 1 | 2015 | 166 | 0.120 |
Why?
|
Child Mortality | 1 | 2016 | 191 | 0.120 |
Why?
|
Abdominal Fat | 1 | 2016 | 223 | 0.120 |
Why?
|
Infant Mortality | 2 | 2016 | 749 | 0.120 |
Why?
|
Quality of Life | 4 | 2007 | 12640 | 0.120 |
Why?
|
Risk Factors | 18 | 2024 | 71974 | 0.120 |
Why?
|
Computer Simulation | 1 | 2007 | 6237 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2015 | 15500 | 0.120 |
Why?
|
Inhibitory Concentration 50 | 2 | 2013 | 464 | 0.110 |
Why?
|
Nucleosides | 2 | 2022 | 138 | 0.110 |
Why?
|
HIV Reverse Transcriptase | 3 | 2010 | 215 | 0.110 |
Why?
|
Botswana | 5 | 2016 | 1034 | 0.110 |
Why?
|
Jaundice | 1 | 2012 | 89 | 0.110 |
Why?
|
Glomerular Filtration Rate | 1 | 2020 | 2184 | 0.110 |
Why?
|
Carotid Arteries | 2 | 2015 | 952 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 643 | 0.100 |
Why?
|
Young Adult | 17 | 2020 | 56255 | 0.100 |
Why?
|
Genotype | 7 | 2012 | 12951 | 0.100 |
Why?
|
Deoxycytidine | 2 | 2014 | 825 | 0.100 |
Why?
|
Myocardial Infarction | 2 | 2023 | 11668 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2016 | 785 | 0.100 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12237 | 0.100 |
Why?
|
Bilirubin | 1 | 2012 | 415 | 0.100 |
Why?
|
Central Nervous System Diseases | 2 | 2005 | 522 | 0.090 |
Why?
|
Survival Analysis | 2 | 2019 | 10247 | 0.090 |
Why?
|
Health Resources | 2 | 2014 | 920 | 0.090 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2014 | 664 | 0.090 |
Why?
|
Antiviral Agents | 2 | 2015 | 2971 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1571 | 0.090 |
Why?
|
Genes, MHC Class I | 1 | 2010 | 257 | 0.090 |
Why?
|
Premature Birth | 2 | 2012 | 1702 | 0.090 |
Why?
|
Clinical Trials as Topic | 3 | 2016 | 7897 | 0.090 |
Why?
|
Models, Biological | 2 | 2010 | 9609 | 0.090 |
Why?
|
Patient Selection | 2 | 2020 | 4211 | 0.090 |
Why?
|
Stillbirth | 1 | 2012 | 346 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3232 | 0.090 |
Why?
|
Polymorphism, Genetic | 4 | 2013 | 4332 | 0.090 |
Why?
|
Cohort Studies | 11 | 2021 | 40389 | 0.090 |
Why?
|
HLA-B Antigens | 1 | 2010 | 352 | 0.090 |
Why?
|
Carotid Artery Diseases | 1 | 2015 | 879 | 0.080 |
Why?
|
Comorbidity | 2 | 2020 | 10362 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 2016 | 1239 | 0.080 |
Why?
|
Coronary Angiography | 4 | 2023 | 4560 | 0.080 |
Why?
|
Genetic Variation | 3 | 2012 | 6539 | 0.080 |
Why?
|
Attitude to Health | 2 | 2016 | 2047 | 0.080 |
Why?
|
Prospective Studies | 13 | 2022 | 53037 | 0.080 |
Why?
|
Aged | 18 | 2023 | 162698 | 0.080 |
Why?
|
Chi-Square Distribution | 2 | 2013 | 3510 | 0.080 |
Why?
|
Epistasis, Genetic | 1 | 2011 | 365 | 0.080 |
Why?
|
Endothelium, Vascular | 1 | 2020 | 4454 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1911 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 1834 | 0.080 |
Why?
|
Bone Density Conservation Agents | 1 | 2015 | 771 | 0.080 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2023 | 4374 | 0.080 |
Why?
|
Half-Life | 2 | 2005 | 658 | 0.080 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2014 | 806 | 0.080 |
Why?
|
Prevalence | 3 | 2022 | 15153 | 0.070 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 24714 | 0.070 |
Why?
|
Birth Weight | 2 | 2012 | 2062 | 0.070 |
Why?
|
Purine Nucleosides | 1 | 2006 | 30 | 0.070 |
Why?
|
Dioxolanes | 1 | 2006 | 25 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2216 | 0.070 |
Why?
|
Drug Administration Schedule | 5 | 2014 | 4935 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2011 | 554 | 0.070 |
Why?
|
Body Mass Index | 5 | 2023 | 12655 | 0.070 |
Why?
|
HIV Fusion Inhibitors | 1 | 2006 | 83 | 0.070 |
Why?
|
United States | 8 | 2023 | 69573 | 0.070 |
Why?
|
Cholesterol | 1 | 2014 | 2900 | 0.070 |
Why?
|
Antigen Presentation | 1 | 2010 | 1286 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2007 | 419 | 0.060 |
Why?
|
Adolescent | 10 | 2020 | 85405 | 0.060 |
Why?
|
Calcium | 1 | 2017 | 5742 | 0.060 |
Why?
|
Endpoint Determination | 2 | 2013 | 598 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2016 | 38942 | 0.060 |
Why?
|
HIV Envelope Protein gp41 | 1 | 2006 | 315 | 0.060 |
Why?
|
Time Factors | 9 | 2019 | 40050 | 0.060 |
Why?
|
Gestational Age | 1 | 2011 | 3486 | 0.060 |
Why?
|
Bone Resorption | 2 | 2019 | 726 | 0.060 |
Why?
|
Immunophenotyping | 2 | 2019 | 1858 | 0.050 |
Why?
|
South Africa | 2 | 2021 | 1743 | 0.050 |
Why?
|
C-Reactive Protein | 2 | 2013 | 3752 | 0.050 |
Why?
|
Thailand | 2 | 2014 | 296 | 0.050 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2023 | 127 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2015 | 3279 | 0.050 |
Why?
|
Genome-Wide Association Study | 4 | 2015 | 12178 | 0.050 |
Why?
|
Sample Size | 1 | 2006 | 845 | 0.050 |
Why?
|
Coronary Vessels | 2 | 2023 | 3097 | 0.050 |
Why?
|
Risk Assessment | 4 | 2022 | 23294 | 0.050 |
Why?
|
Antibodies, Viral | 2 | 2023 | 3151 | 0.050 |
Why?
|
Africa | 2 | 2015 | 666 | 0.050 |
Why?
|
Drug Therapy | 2 | 2015 | 497 | 0.050 |
Why?
|
Floxuridine | 1 | 2000 | 47 | 0.050 |
Why?
|
Research | 1 | 2010 | 2001 | 0.050 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2020 | 35 | 0.050 |
Why?
|
Patient Compliance | 3 | 2007 | 2679 | 0.050 |
Why?
|
Statistical Distributions | 1 | 2020 | 64 | 0.050 |
Why?
|
Mutation, Missense | 1 | 2010 | 2552 | 0.050 |
Why?
|
North America | 1 | 2024 | 1249 | 0.050 |
Why?
|
Mutation | 6 | 2021 | 29658 | 0.050 |
Why?
|
Infusion Pumps, Implantable | 1 | 2000 | 156 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6516 | 0.050 |
Why?
|
Least-Squares Analysis | 1 | 2000 | 382 | 0.050 |
Why?
|
Adipose Tissue | 2 | 2023 | 3280 | 0.050 |
Why?
|
Integrases | 1 | 2022 | 532 | 0.050 |
Why?
|
Genetic Testing | 1 | 2012 | 3441 | 0.040 |
Why?
|
Parathyroid Hormone | 2 | 2017 | 1799 | 0.040 |
Why?
|
Proteomics | 2 | 2023 | 3584 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 202 | 0.040 |
Why?
|
Placebos | 2 | 2016 | 1678 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 12328 | 0.040 |
Why?
|
Pilot Projects | 4 | 2015 | 8275 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2012 | 5462 | 0.040 |
Why?
|
Mood Disorders | 1 | 2005 | 1102 | 0.040 |
Why?
|
Pregnancy | 7 | 2016 | 29002 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2023 | 719 | 0.040 |
Why?
|
Lipids | 3 | 2016 | 3307 | 0.040 |
Why?
|
Blood Proteins | 1 | 2023 | 1122 | 0.040 |
Why?
|
Blood Glucose | 3 | 2021 | 6237 | 0.040 |
Why?
|
Biological Availability | 1 | 2017 | 390 | 0.040 |
Why?
|
Transsexualism | 1 | 2020 | 173 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15036 | 0.040 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2000 | 640 | 0.040 |
Why?
|
India | 2 | 2014 | 2189 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2018 | 425 | 0.040 |
Why?
|
Drug Interactions | 1 | 2020 | 1456 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2020 | 21694 | 0.030 |
Why?
|
Drug Combinations | 2 | 2014 | 1959 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2005 | 2261 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2345 | 0.030 |
Why?
|
Therapeutic Equivalency | 1 | 2014 | 143 | 0.030 |
Why?
|
Longitudinal Studies | 3 | 2015 | 13880 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2017 | 575 | 0.030 |
Why?
|
Asia | 1 | 2015 | 604 | 0.030 |
Why?
|
Linear Models | 2 | 2016 | 5948 | 0.030 |
Why?
|
Developing Countries | 2 | 2016 | 2779 | 0.030 |
Why?
|
International Cooperation | 1 | 2020 | 1420 | 0.030 |
Why?
|
Malawi | 1 | 2014 | 282 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2006 | 5076 | 0.030 |
Why?
|
Pelvic Bones | 1 | 2015 | 264 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10945 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2013 | 380 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2014 | 423 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 2913 | 0.030 |
Why?
|
Osteoprotegerin | 1 | 2013 | 174 | 0.030 |
Why?
|
Pyridazines | 1 | 2014 | 204 | 0.030 |
Why?
|
Minority Groups | 1 | 2020 | 1197 | 0.030 |
Why?
|
Triglycerides | 1 | 2020 | 2447 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2023 | 2583 | 0.030 |
Why?
|
Birth Certificates | 1 | 2011 | 67 | 0.030 |
Why?
|
Infant, Newborn | 4 | 2013 | 25470 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2016 | 792 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2022 | 2716 | 0.030 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2011 | 58 | 0.030 |
Why?
|
RANK Ligand | 1 | 2013 | 325 | 0.030 |
Why?
|
Meningioma | 1 | 2000 | 1202 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3524 | 0.020 |
Why?
|
Hypertension | 1 | 2011 | 8431 | 0.020 |
Why?
|
Disease Progression | 3 | 2014 | 13237 | 0.020 |
Why?
|
Metabolism, Inborn Errors | 1 | 2013 | 288 | 0.020 |
Why?
|
Meningeal Neoplasms | 1 | 2000 | 1234 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4522 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2184 | 0.020 |
Why?
|
Receptors, Drug | 1 | 2011 | 161 | 0.020 |
Why?
|
Chemoprevention | 1 | 2013 | 323 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 6174 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 228 | 0.020 |
Why?
|
Biometry | 1 | 2013 | 558 | 0.020 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 2011 | 150 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 3757 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1050 | 0.020 |
Why?
|
HIV Antigens | 1 | 2010 | 343 | 0.020 |
Why?
|
Tanzania | 1 | 2014 | 1303 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2015 | 4424 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2019 | 2334 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2015 | 1726 | 0.020 |
Why?
|
Nitriles | 1 | 2014 | 946 | 0.020 |
Why?
|
Spouses | 1 | 2011 | 283 | 0.020 |
Why?
|
Infant, Small for Gestational Age | 1 | 2011 | 438 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3722 | 0.020 |
Why?
|
Dreams | 1 | 2009 | 147 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2023 | 4920 | 0.020 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2008 | 53 | 0.020 |
Why?
|
Gene Dosage | 1 | 2012 | 1251 | 0.020 |
Why?
|
Breast Feeding | 1 | 2016 | 1334 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14740 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 562 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7298 | 0.020 |
Why?
|
Adiponectin | 1 | 2013 | 1096 | 0.020 |
Why?
|
Sex Factors | 2 | 2011 | 10398 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4013 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 1453 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2022 | 10455 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2012 | 1689 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5959 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2013 | 1356 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2010 | 596 | 0.020 |
Why?
|
Weight Gain | 1 | 2016 | 2278 | 0.020 |
Why?
|
Antigens, CD | 1 | 2016 | 4024 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1244 | 0.020 |
Why?
|
Leptin | 1 | 2013 | 1589 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2010 | 1793 | 0.020 |
Why?
|
Sulfonamides | 1 | 2014 | 1934 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2000 | 4216 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2011 | 1309 | 0.020 |
Why?
|
Stavudine | 1 | 2004 | 86 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2881 | 0.020 |
Why?
|
Diet | 1 | 2022 | 7876 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2782 | 0.010 |
Why?
|
Counseling | 1 | 2012 | 1526 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3194 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18349 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 5154 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2694 | 0.010 |
Why?
|
Gene Frequency | 1 | 2010 | 3585 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15511 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8274 | 0.010 |
Why?
|
Brain | 1 | 2009 | 26345 | 0.010 |
Why?
|
Protein Conformation | 1 | 2010 | 4012 | 0.010 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2004 | 419 | 0.010 |
Why?
|
Pyrimidines | 1 | 2014 | 2918 | 0.010 |
Why?
|
Lactic Acid | 1 | 2007 | 1132 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2546 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5293 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2000 | 6726 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5460 | 0.010 |
Why?
|
Algorithms | 1 | 2000 | 13872 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5941 | 0.010 |
Why?
|
Area Under Curve | 1 | 2004 | 1655 | 0.010 |
Why?
|
Genome, Human | 1 | 2012 | 4419 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6942 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2000 | 8791 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9684 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2010 | 2950 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2012 | 76631 | 0.010 |
Why?
|
Computational Biology | 1 | 2011 | 3506 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 20913 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2002 | 12985 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7274 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6452 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2009 | 6963 | 0.010 |
Why?
|
Software | 1 | 2011 | 4423 | 0.010 |
Why?
|
Blotting, Western | 1 | 2004 | 5181 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13402 | 0.010 |
Why?
|
Anxiety | 1 | 2009 | 4253 | 0.010 |
Why?
|
Neoplasms | 2 | 2014 | 21507 | 0.010 |
Why?
|
Infant | 1 | 2016 | 34923 | 0.010 |
Why?
|
Liver | 1 | 2010 | 7449 | 0.010 |
Why?
|
Child | 1 | 2022 | 77033 | 0.010 |
Why?
|
Child, Preschool | 1 | 2016 | 40802 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2007 | 3858 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 35326 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2012 | 57650 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2006 | 13002 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 11699 | 0.010 |
Why?
|
Depression | 1 | 2009 | 7689 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2000 | 8605 | 0.000 |
Why?
|
Phenotype | 1 | 2004 | 16301 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2000 | 19811 | 0.000 |
Why?
|